English हिंदी
  • भारत सरकार के विज्ञान एवम प्रौदयोगिकी मंत्रालय के जैव प्रौदयोगिकी विभाग की स्वायत्त संस्थान
  • AN AUTONOMOUS INSTITUTE OF DEPT. OF BIOTECHNOLOGY, MINISTRY OF SCIENCE AND TECHNOLOGY, GOVT OF INDIA
  • होम
  • संकाय प्रोफ़ाइल

DR.RUCHI TANDON

Ph.D.

SENIOR RESEARCH SCIENTIST

  • Ph.D.
  • PhD, CSIR-Central Drug Research Institute, Lucknow
  • Postdoctoral Research Associate, National Institute of Immunology, New Delhi
  • Postdoctoral Research Associate, Wayne State University, MI, USA
  • Drug Discovery Research: Led and managed the discovery portfolio of early discovery programs on complex human diseases such as metabolic and inflammatory disorders as well as oncology utilizing the small molecule and natural products formulations for their pre-clinical development while working with inter-disciplinary institutional and global teams in leading pharmaceutical companies during 2002-2017.

 

Current Interests: Non-alcoholic fatty liver disease

NAFLD is a slow-progressing disease with aberrant lipid metabolism, inflammation, oxidative stress, and fibrosis which has nearly 30 % global prevalence with no treatment options available to date. Current focus of my lab is to understand the pathophysiology and identify potential therapeutic options for the management of  Non-alcoholic fatty liver disease(NAFLD) and associated comorbidities.

My lab has established in vitro and in vivo models to perform pre-clinical assesment of small chemical entities as well as natural product formulations to identify potential therapeutic options for the management of NAFLD. 

Apart from conventional 2D models my lab has established multilineage 3D spheroid models mimicking the liver heterogeneity to test the anti-steatotic, anti-inflammatory and anti-fibrotic properties of test compounds.

Short-listed molecules as a result of this exercise are further evaluated for their pharmaco-kinetic analysis followed by screening in the in vivo models of NAFLD using mice fed with different types of carbohydrate and fat rich diets.  

My lab also has a keen interest in understanding the role of different members of inflammasome family in progression of NAFLD and their correlation with different diets in animals and patients using metabolites and gene expression studies in different metabolic tissues.   

/var/folders/d3/_xrxflp51r99k2z8zcf7n4340000gn/T/com.microsoft.Word/Content.MSO/E01F0D47.tmp                                                                                               

Establishment of Liver Organoid Platform

To overcome the issues related to the translation of the in vitro findings into the in vivo set ups and later at the clinical stage, we need more realistic screening models. My lab has therefore established human liver organoids using healthy humans and NAFLD patients derived liver tissues as a platform to conduct drug discovery research and to understand the pathophysiology of NAFLD. 

/var/folders/d3/_xrxflp51r99k2z8zcf7n4340000gn/T/com.microsoft.Word/Content.MSO/65E6ADED.tmp

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publication

2023 

§ Kumari D, Gautam J, Sharma V, Gupta S, Sarkar S, Jana P, Singhal V, Babele P, Kamboj P,  Bajpai S, Tandon R, Kumar Y, Dikshit M. Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice, HELIYON (2023), doi:       https:// doi.org/10.1016/j.heliyon.2023.e22051.

§ Sharma PK, Verma L, Goswami Y, Pujani M, Dikshit M*, Tandon R* The aqueous root extract of Withania somnifera ameliorates LPS-induced inflammatory changes in the in vitro cell-based and mice models of inflammation Front. Pharmacol., (2023)14:1139654. doi: 10.3389/fphar.2023.1139654 (*Corresponding Author)

§ Soni A, Saha S, Agarwal A, Rauf ARA, Singh RK, Seth M,   Singh SK, Sinha S, Shirumalla RK, Marumoto S, Tandon R* 2-{N-[(2,4,5-trichlorophenoxy) acetyl]-N-methylamino}-3-pyrrolidinepropanamides analogs as potential antagonists of Urotensin-II receptor,  J Recep Sig Trans, 2022, 2023 Feb;43(1):1-8. doi: 10.1080/10799893.2022.2164306. Epub 2023 Jan 18. (*Corresponding author).

§ Sharma P, Nandave M, Nandave D, Yadav S, De-Le_Cruz CV, Singh S, Tandon R, Ramniwas S, Behl T. Reactive oxygen species(ROS)-mediated oxidative stress in chronic liver diseases and its mitigation by medicinal plants. Am J Trans Research. 2023, 15(10)

2022

§  Visaga SA,  Kalonia H,  Verma V,  Sinha S,  Singh SK,  Upadhyay S, Sahdev S,  Pansari P,  Kumar R,  Bandgar M, Karanjule N, Shirumalla RK,  Morishita K, Tandon   R* Developing selective FPR2 agonists can be a potential approach to treat moderate to severe asthma(2022) J Clin Toxicol, Vol.12 (3)1000510 (*Corresponding author)

§  Singh RK, Sodhi R, Sharma S, Dastidar SG, Tandon R*. Targeting MAPAKAP2(MK2) to combat inflammation by avoiding the differential regulation of anti-inflammatory   genes by p38 MAPK inhibitors. BioRxiv doi:https://doi.org/10.1101/2022.07.17.500377 2022 (*Corresponding author)

2020 and earlier

§  Tandon R*, Soni A., Singh R.K., Sodhi R., Seth MK.,  Sinha S., Dhage G., Das B., Dastidar SG, Shriumalla RK. Marumoto S, Nagayama T. Identification of novel Urotensin-II  receptor antagonists with potent inhibition of U-II induced pressor response in mice (2020) Euro J Pharmacol  886:173391.DOI: 10.1016/j.ejphar.2020.173391, PMID: 32745605 (*Corresponding author)

§  Soni A, Agarwal A, Saha S, Shripati KR, Das M, Das B, Cliffe I, Tandon R, Singh RK, Dastidar S, Singh SK, Sinha S, Shriumalla RK, Semwal VP, Marumoto S, Nagayama T. Design, synthesis, and SAR of 2-acetamido-3-pyrrolidinepropanamide derivatives as Urotensin-II receptor antagonists, 250th American Chem Soc.  National Meetings and Expositions, Boston, MA, USA, 2015

§  Tandon R*, Senthil V., Nithya D., Venkataramanan R.,  Pamidiboina V., Kumar A, Malik S, Chaira T, Diwan M, Gupta P, Venkataramanan R, Malik R, Das B, Dastidar SG, Cliffe IA; Ray A; Bhatnagar PK. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy (2013) Euro J Pharmacol 711(1-3):19-26. DOI: 10.1016/j.ejphar.2013.04.016PMID: 23639757(*Corresponding author)

§  Singh RK, Tandon R, Dastidar SG, Ray A. A review on leukotrienes and their receptors with reference to asthma (2013) J Asthma 50(9):922-931.    DOI: 10.3109/02770903.2013.823447PMID: 23859232 

§  Tandon R*, Kapoor S, Vali S, Senthil V., Nithya D., Venkataramanan R, Sharma A, Talwadkar A, Ray A, Bhatnagar PK and Dastidar SG. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: A novel approach for overcoming resistance in anticancer treatment (2011) Euro  J Pharmacol 667(1-3):5665. DOI: 10.1016/j.ejphar.2011.04.066  PMID: 21640718  (Corresponding author)

 

§ Tiwari P, Saini S,  Upmanyu S, Benjamin B,  Tandon R, Saini KS and Sahdev S. Enhanced expression of recombinant proteins utilizing a modified baculovirus expression vector.(2010) Mol  Biotechnology 46(1):80-9.  DOI: 10.1007/s12033-010-9284-3 PMID: 20424933

§  Tandon R, Singh MP, Haq W, Dixit M, Patnaik GK and Dhar MM (2010) Design and synthesis of novel tetrapeptides as potential ACE inhibitors.Cheminformatics 28, 40.

§  Subhadra LB,  Sundaresan S,  Singaravelu A,  Kadapakkam SN,  Badri NR, Katiyar C,  Kanaujia  A, Duggar R, Singh Y,  Konasubrahmanya S,  Bansal V, Sarin S,  Tandon   R,  Sharma S and Singh S. (2009) Cinnamic acid isolated from the bark of Cinnamomum cassia regulates glucose transport through activation of glucose transporter 4 on L6 myotubes in a PI3 Kinase independent fashion. J Diabetes 1, 99-106. DOI: 10.1111/j.1753-0407.2009.00022.xPMID: 20929506

§  Soni A, Agarwal A, Saha S, Das M, Shripati K, Aeron S, Das B, Cliffe I, Tandon R, Singh R, Sodhi R. Design, synthesis, and SAR of 2-acetamido-3-pyrrolidinepropanamide derivatives as urotensin-II receptor antagonists. Abstracts of the papers of the American Chemical Society 2015 Aug 16 (Vol. 250). 1155 16TH ST, NW, Washington, DC 20036 USA: AMER CHEMICAL SOC.

§ Tandon R*, Gupta A, Ray A (2013)  Mechanism of action of antidiabetic property of cinnamic acid, a principal active ingredient from the bark of Cinnamomum cassia. Int J Therap Appls, 9, 2013, 39-45.  (*Corresponding author)

§  Zhang M, Deng Y, Tandon R, Bai C, Riedel H. ( 2008) Essential role of PSM/SH2-B variants in insulin receptor catalytic activation and the resulting cellular responses J Cell Biochem, 1;103(1):162-81. DOI: 10.1002/jcb.21397PMID: 17615553

§  Sarma PK, Tandon R, Gupta P, Dastidar SG, Ray A, Das B, Cliffe IA(2007) Progress in the  development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase. Exp Opin Ther Pat 17(1) 25-35 (11) https://doi.org/10.1517/13543776.17.1.25

§ Mittra S, Sangle G, Tandon R, Sharma S, Roy S, Khanna V, Gupta A, Sattigeri J, Sharma L,  Khattar SK, Bora RS, Saini KS, Bansal VS (2007) Increase in weight induced by   muraglitazar, a dual PPAR alpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol, 150(4):480-7.  DOI: 10.1038/sj.bjp.0707000 PMID: 17211457

§  Deng Y, Bhattacharya S, Swamy OR, Tandon R, Wang Y, Janda R, Riedel H.(2003) Growth factor receptor binding protein 10 (Grb10) as a partner of PI 3kinase in metabolic insulin action. J Biol Chem; 278(41):39311-22.   DOI: 10.1074/jbc.M304599200PMID: 12783867 

§  Singh SB*, Tandon R*, Krishnamurthy G, Vikram R, Sharma N, Basu SK and Mukhopadhyay A (2003) Rab5-mediated endosome-endosome fusion regulates hemoglobin endocytosis in Leishmania donovani. EMBO J; 22(21) :5712-22.   DOI: 10.1093/emboj/cdg557PMID: 14592970 (Co-first author*)

§  Narayan P, Pandey R, Yadav VS, Tandon R, Haq W, Dhar MM , Singh VK (2003). Inhibition of anti-CD3 and interleukin-2 stimulated T lymphocyte proliferation by   peptidomimetic opioid compound. Immunopharmacol Immmunotox ;25(2):225-33. DOI: 10.1081/iph-120020472  PMID: 12784915

§ Narayan P, Tandon R, Haq W, Dhar and MM Singh VK (2002) Inhibition of antigen specific lymphocyte proliferation and cytokine stimulation by peptidomimetic opioid   compound. Int Immunopharmacol 2 :751-757. DOI: 10.1016/s1567-5769(02)00011-5PMID: 12095165

§  Narayan P, Singh VK, Agarwal SS, Tandon R, Haq W, Raghubir R and Dhar MM (2001) Immunomodulation by Opioid Peptidomimetic   Compound. Neuroimmunomodulation 9:134-40.   doi: 10.1159/000049017. PMID: 11752886

§  Sengupta S, Tripathi J, Tandon R, Roy RP, Basu SK and Mukhopadhyay A (1999) Hemoglobin endocytosis in Leishmania is mediated through a 46 kD protein located in   flagellar pocket. J Bio Chem  274(5), 2758-2765.  DOI: 10.1074/jbc.274.5.2758PMID: 9915807

§ Tandon R, Singh MP, Haq W, Dikshit' M, Patnaik  GK, Dhar MM (1997), Synthesis of novel tetrapeptides as potential ACE inhibitors. I J Chem, 36B.

§  Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H  (2001). Mus musculus Pro-rich, PH and SH2 domain-containing signaling mediator alpha mRNA, complete   cds, alternatively spliced. NCBI GenBank; Accession number AF421138.

§  Yousaf  N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H (2001). Mus musculus Pro-rich, PH and SH2 domain-containing signaling mediator gamma mRNA,   complete cds, alternatively spliced. NCBI GenBank Accession number AF421139.

§  Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H(2001). Mus musculus PSM/SH2-B delta (Sh2B psm1) mRNA, complete cds. NCBI GenBank Accession   number AF380422.

1. Team including Tandon R, Chauthaiwale V et al Heat shock protein inducers in myocardial and cerebral ischemia. (2004) Torrent pharmaceuticals ltd.           Gujarat, India, Pct File No. Pct/in05/00112, Patent File No. 178/kol/2004

2. Team including Tandon R, Dhar MM et al ."An improved process for the preparation of polypeptide useful as Gonadotropin Releasing Hormone agonist       having C-Terminal Proline ethylamide". Patent application No. 3069/DEL/97

  • CSIR Fellowship  
  • International Travel award, National Research Center for Biotechnology, Braunschweig, Germany, 1999
  • Postdoctoral Research Associate, Wayne State University, MI, USA (National Institute of Health, Bethesda, USA Fellowship) 2000
  • Individual Excellence Award, Ranbaxy Research Labs, 2006 
  • Assistant Director, Daiichi Sankyo Pharma, 2010
  • Group Head Pharmacology, 2012
  • Star Team award, Daiichi Sankyo, 2012 
  • SMART Team award, Daiichi Sankyo, 2013 
  • Assistant Director and Group Head, Pharmacology, Daiichi Sankyo Pharma, 2014
  • Reviewer international peer reviewed journals; PLOS One, Oncology Rev and Frontiers in Pharmacology, Biomedicine and Pharmacotherapy
  • Member, Editorial Board, Frontiers in Pharmacology

NCBI Nucleotide Accessions 

1- Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H (2001) Mus musculus Pro-rich, PH and SH2 domain containing signaling mediator alpha mRNA, complete     cds, alternatively spliced. NCBI GenBank accession number AF421138, GI: 16226080 

2- Yousaf N, DengY, Tandon R, Cheng DW, KangY and Riedel H (2001) Mus musculus Pro-rich, PH and SH2 domain containing signaling mediator gamma mRNA, complete       cds, alternatively spliced. NCBI GenBank accession number AF421139, GI 16226077

3- Yousaf N, Deng Y, Tandon R, Cheng DW, Kang Y and Riedel H(2001) Mus musculus PSM/SH2-B delta (Sh2B psm1) mRNA, complete cds. NCBI GenBank accession   number  AF380422, GI: 15787982

  • 01292876492
  • RUCHI[DOT]TANDON[AT]THSTI[DOT]RES[DOT]IN